Roswell Park Comprehensive Cancer Center investigators will deliver 21 presentations at the AHNS 12th International Conference on Head and Neck Cancer.
|Videos|July 25, 2017
Dr. Cohen Discusses NK-Directed Therapy in Head and Neck Cancer
Author(s)Ezra Cohen, MD
Ezra Cohen, MD, associate director, Moores Cancer Center at the University of California, San Diego, discusses natural killer-directed therapy in head and neck cancer.
Advertisement
Ezra Cohen, MD, associate director, Moores Cancer Center at the University of California, San Diego, discusses natural killer (NK)-directed therapy in head and neck cancer.
Cohen says that NK cell-directed therapies can manipulate NKs ex vivo and then reinfuse them, or even create NKs from regular stem cells from the blood or skin.
Advertisement
Related to this article
Trastuzumab deruxtecan did not meet the prespecified efficacy criterion in HER2-low salivary gland carcinoma, though responses were observed in salivary duct carcinoma.
The FDA approved selpercatinib for RET fusion–positive advanced solid tumors.
Neoadjuvant and adjuvant pembrolizumab improved EFS across surgical outcome subgroups in resectable head and neck squamous cell carcinoma.
Advertisement
Advertisement
Trending on OncLive
1
The OncFive: Top Oncology Articles for the Week of 7/12
2
CD33-Directed CAR T-Cell Therapies Elicit Complete Remissions in Relapsed/Refractory AML
3
Five Under 5: Top Oncology Videos for the Week of 7/12
4
Subcutaneous Pembrolizumab Faces Scrutiny Over Convenience and Cost for Patients With Cancer
5